Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

O3 FEB 14 PH 1:

# **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Abbott Laboratories	
2. Registrant Address	Suite 200 DC 20005 United States
3. Principal Place of Business (if different from line 2)  City Abbott Park State/Zip (or Country)	IL 60064 United States
1. 001111111111111111111111111111111111	1 (optional)  5. Senate ID #  66-12
7. Client Name X Seif	6. House ID # 30001000
INCOME OR EXPENSES - Complete Eithe  12. Lobbying Firms	r Line 12 <b>OR</b> Line 13  13. Organizations
INCOME relating to lobbying activities for this reporting period was:  Less than \$10,000   \$10,000 or more   >> \$  Income (nearest \$20,000)  Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	EXPENSES relating to lobbying activities for this repperiod were:  Less than \$10,000   \$10,000 or more
	Method A. Reporting amounts using LDA defining Method B. Reporting amounts under section 603 the Internal Revenue Code

Signature	Date <u>2/14/2003</u>	_
Printed Name and Title	Cynthia B. Sensibaugh - Director, Federal Government Affairs	]

Registrant Name:	Abbott Laboratories	
Client Name:	Abbott Laboratories	
engaged in lobbyi	TIVITY. Select as many codes as necessaring on behalf of the client during the reportinguested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ag period. Using a separate page for each code, provide
15. General issu		
16. Specific Lol	obying issues	
Act, 2003,	funding for Special Supplemental Feeding	Food and Drug Administration, and Related Agencies Ap g program for Women, Infants and Children. d Human Services, and Education, and Related Agencies Drug Assistance programs under the Ryan White Act.
17. House(s) o House of I Senate	f Congress and Federal agencies contacted Representatives	☐ Check if None
18. Name of e	ach individual who acted as a lobbyist in this	
Name		Covered Official Position (if applicable)
Haas, Ro	semary T.	
	orth, Elaine R.	
	Howard D.	

Signature	Date _2/14/2003
Printed Name and Title	Cynthia B. Sensibaugh - Director, Federal Government Affairs

Regi	strant Name:	Abbott Laboratories	
Clier	nt Name:	Abbott Laboratories	
enga	ged in lobbying	TVITY. Select as many codes as necessary to on behalf of the client during the reporting ested. Attach additional page(s) as needed.	o reflect the general issue areas in which the registrant period. Using a separate page for each code, provide
15.	General issue	area code <u>CPT</u> (one per page)	
16.	Specific Lobb	ying issues	
	H.R.5272, Pr	812, Greater Access to Affordable Pharms rescription Drug Fair Competition Act of rescription Drug Affordability Act.	aceuticals Act of 2001. 2002.
17.		Congress and Federal agencies contacted presentatives	☐ Check if None
18.	Name of each	n individual who acted as a lobbyist in this is	
	Name		Covered Official Position (if applicable)
	Haas, Rosen	nary T.	
	Leavenwort	h, Elaine R.	
	Sensibaugh	Cynthia B.	
19.	Interest of ea	ach foreign entity in the specific issues listed	on line 16 above

Signature	Date 2/14/2003	
Printed Name and Title	Cynthia B. Sensibaugh - Director, Federal Government Affairs	_ ]

Regi	strant Name:	Abbott Laboratories	
Clier	nt Name:	Abbott Laboratories	
enga	ged in lobbyin	TVITY. Select as many codes as necessary g on behalf of the client during the reporting tested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant period. Using a separate page for each code, provide
15.			
16.	Specific Lobb	ying issues	
	S.2244, Press S.812, Great drugs.	cription Drug Price Parity for Americans er Access to Affordable Pharmaceuticals	Act, Act of 2001, amendment relating to reimportation of p
17.		Congress and Federal agencies contacted presentatives	☐ Check if None
18.	Name of each	n individual who acted as a lobbyist in this is	ssue area
	Name		Covered Official Position (if applicable)
	Haas, Roser	nary T.	
	Leavenwort		
		, Cynthia B.	
<del></del>			
19.	Interest of ea	ach foreign entity in the specific issues listed	on line 16 above Mr Check if None

Signature	Date Date	
	Cynthia B. Sensibaugh - Director, Federal Government Affairs	
Printed Name and Title	Cynthia B. Sensibaugh - Director, Federal Government Amaris	i

Regis	strant Name:	Abbott Laboratories	
Clier	nt Name:	Abbott Laboratories	
enga	ged in lobbying	TVITY. Select as many codes as necessary g on behalf of the client during the reporting ested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant period. Using a separate page for each code, provide
15.	General issue	area code MMM (one per page)	
16.	Specific Lobb	ying issues	
	H.R.1624/S.5 H.R.2063/S.5 H.R.4954, M benefit, comp method for c S.2, 21st Cen S.2625, Med S.3018, Bene	petitive bidding for durable medical equi linical laboratory tests. Itury Medicare Act, Icare Outpatient Prescription Drug Act	001, 01, Drug Act of 2002 , provisions relating to Medicare pres pment under Medicare Part B and reform of the reimb
17.	Centers for	Congress and Federal agencies contacted Medicare and Medicaid Services of Health & Human Services presentatives	☐ Check if None
18.	Name of each	n individual who acted as a lobbyist in this is	ssue area
	Name		Covered Official Position (if applicable)
	Haas, Rosen	nary T.	
<del></del>	Leavenwort	h, Elaine R.	
	Sensibaugh.		
	Witenstein,		
			I
19.	Interest of ea	ch foreign entity in the specific issues listed	on line 16 above

Signature	Date 2/14/2003
· ·	
Printed Name and Title	Cynthia B. Sensibaugh - Director, Federal Government Affairs

Registra	int Name: Abbott Laboratories	
Client N	Name: Abbott Laboratories	
Item	Description	Data
16 16	Lobbying Issues Lobbying Issues	S.3098, Medicare Competitive Acquisition Act of 2002, Medicare local medical review policies.
		Ensure adequate Medicare reimbursement for new technologies to increase the safety of the blood supply
		Medicaid rebate system
		Medicare compliance
		Drug discount card programs

Regi	strant Name:	Abbott Laboratories	
Clien	nt Name:	Abbott Laboratories	
enga	ged in lobbying	TVITY. Select as many codes as necessary to on behalf of the client during the reporting ested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant period. Using a separate page for each code, provide
	General issue		
16.	Specific Lobb	ying issues	
	H.R.1786, To S.847, A bill	o impose tariff-rate quotas on certain case to impose tariff-rate quotas on certain ca	ein and milk protein concentrates, sein and milk protein concentrates,
	USDA impoi	t permits	
	Internationa	l intellectual property protection	
	World Healt	h Organization initiatives regarding infa	nt formula
17.	House of Rep Senate	Congress and Federal agencies contacted presentatives  s Trade Representative	□ Check if None
18.	Name of each	n individual who acted as a lobbyist in this is	sue area
	Name		Covered Official Position (if applicable)
	Haas, Rosen	nary T.	
	Leavenwort	h, Elaine R.	
	Scholick, Ho	oward D.	
	Sensibaugh	Cynthia B.	
	·		
			1
19.	Interest of ea	ch foreign entity in the specific issues listed	on line 16 above

Signature	Date <u>2/14/2003</u>	
Printed Name and Title	Cynthia B. Sensibaugh - Director, Federal Government Affairs	I

Regi	strant Name:	Abbott Laboratories			
Client Name:		Abbott Laboratories			
enga	iged in lobbying	<b>IVITY.</b> Select as many codes as necessary on behalf of the client during the reporting ested. Attach additional page(s) as needed.	to reflect the general issue areas in which the registrant period. Using a separate page for each code, provide		
15.	. General issue area code <u>UTI</u> (one per page)				
16.	Specific Lobb	ying issues			
	H.R.4, SAFE Act of 2001 Securing America's Future Energy Act of 2001, S.517, National Laboratories Partnership Improvement Act of 2001,				
17.	House of Rep	ongress and Federal agencies contacted presentatives	☐ Check if None		
	Senate				
18.	8. Name of each individual who acted as a lobbyist in this issue area				
	Name		Covered Official Position (if applicable)		
	Haas, Rosen	nary T.			
	Leavenwortl	n, Elaine R.			
	·····				
19.	Interest of ea	ch foreign entity in the specific issues listed	on line 16 above		

Filing #880ae61d-109b-492c-aaa0-71a4e4b8c8ae - Page 15 of 16